Clinical Study to Evaluate the Pharmacokinetic Characteristics Between TMX-67 and Feburic® in Healthy Volunteers
PHASE1CompletedINTERVENTIONAL
Enrollment
30
Participants
Timeline
Start Date
January 31, 2012
Primary Completion Date
February 29, 2012
Study Completion Date
February 29, 2012
Conditions
Gout
Interventions
DRUG
Feburic®
80 mg\*1 tablet
DRUG
TMX-67
40 mg\*2 tablets
Trial Locations (1)
Unknown
Korea University Anam Hospital, Seoul
All Listed Sponsors
lead
SK Chemicals Co., Ltd.
INDUSTRY
NCT01563432 - Clinical Study to Evaluate the Pharmacokinetic Characteristics Between TMX-67 and Feburic® in Healthy Volunteers | Biotech Hunter | Biotech Hunter